Publication of List of Manufacturers revoked from licensing for the manufacture of Therapeutic Goods – 22 November 2024

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament of Australia, was introduced to regulate the provision and use of therapeutic goods to ensure they are safe, of acceptable quality, and perform as claimed. This Act aims to protect public health by controlling the importation, supply, and manufacturing of therapeutic goods, which include medicines, medical devices, and other health-related products. The Act also facilitates access to therapeutic goods that are needed for public health and medical purposes. In exercising its powers under the Act, the Therapeutic Goods Administration (TGA) can revoke the licences of manufacturers who no longer meet the required standards or have requested the revocation of their licence, as evidenced by the recent revocation of the licences of Biomebank and Baxter Healthcare Pty Ltd. This action underscores the TGA’s commitment to maintaining high standards in the therapeutic goods industry, ensuring that only entities that comply with regulatory requirements are permitted to manufacture these critical products.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the manufacture, importation, supply, or advertisement of therapeutic goods within Australia. This includes companies, individuals, and other legal entities that produce or distribute therapeutic products such as medicines, medical devices, and blood products. The Act's reach is national, governing the entire Commonwealth of Australia, and it extends to ensuring that all therapeutic goods meet quality, safety, and efficacy standards. The Act allows for the licensing of therapeutic goods manufacturers and includes provisions for the revocation of such licenses if certain criteria are not met. Notably, the Act applies to all therapeutic goods irrespective of their intended use, including prescription and over-the-counter medications, as well as therapeutic devices. The Act does not apply to substances that are regulated under other federal or state legislation, such as certain agricultural chemicals or food products. The Act also allows for the creation of subordinate instruments that can extend or restrict its application, ensuring flexibility and responsiveness to emerging issues in therapeutic goods regulation.

Key Provisions

Section 41(1)(e) of the Therapeutic Goods Act 1989 allows the Secretary to revoke a licence to manufacture therapeutic goods at the request of the manufacturer. This revocation process is significant as it formally removes the manufacturer's authority to produce therapeutic goods, which are substances or devices intended for use in diagnosing, treating, or preventing diseases. The Act specifies that such revocations are made by written notice, as evidenced in the notice published by Katherine Clark, Delegate of the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, on 22 November 2024. The notice lists two specific manufacturers, Biomebank and Baxter Healthcare Pty Ltd, whose manufacturing licences have been revoked at their request. The Therapeutic Goods Act 1989 imposes certain obligations on the entities it governs, particularly those holding manufacturing licences. These entities are required to adhere to stringent quality and safety standards to ensure that the therapeutic goods they produce are safe and effective. Manufacturers must maintain proper records, conduct regular self-inspections, and report any adverse events or quality issues to the Therapeutic Goods Administration. Failure to comply with these obligations can lead to further regulatory actions, including potential licence suspension or revocation. Under the Therapeutic Goods Act 1989, breaches of the Act's provisions can result in both civil and criminal consequences. For instance, manufacturing therapeutic goods without a valid licence or failing to comply with the quality and safety standards can lead to substantial fines and even imprisonment. The maximum penalties vary depending on the severity and nature of the breach, with serious offences potentially resulting in fines of up to $2,200,000 for corporations and imprisonment for up to 10 years. Additionally, the court may order the confiscation of the goods produced in breach of the Act, further emphasising the importance of compliance with the regulatory framework.